Lazard Capital Markets boosted their price objective on shares of Aratana Therapeutics (NASDAQ:PETX) from $28.00 to $39.00 in a research note issued on Tuesday, Stock Ratings News reports. The firm currently has a “buy” rating on the stock. Lazard Capital Markets’ target price indicates a potential upside of 40.95% from the stock’s previous close.
A number of other analysts have also recently weighed in on PETX. Analysts at William Blair initiated coverage on shares of Aratana Therapeutics in a research note to investors on Tuesday, July 23rd. They set an “outperform” rating on the stock. Separately, analysts at Craig Hallum initiated coverage on shares of Aratana Therapeutics in a research note to investors on Monday, July 22nd. They set a “buy” rating on the stock. Finally, analysts at JMP Securities initiated coverage on shares of Aratana Therapeutics in a research note to investors on Monday, July 22nd. They set an “outperform” rating and a $16.00 price target on the stock. Five analysts have rated the stock with a buy rating, Aratana Therapeutics has an average rating of “Buy” and a consensus target price of $22.67.
Shares of Aratana Therapeutics (NASDAQ:PETX) traded up 8.72% on Tuesday, hitting $27.67. The stock had a trading volume of 311,216 shares. Aratana Therapeutics has a one year low of $6.56 and a one year high of $26.66. The stock’s 50-day moving average is $14.65 and its 200-day moving average is $11.68. The company’s market cap is $605.8 million.
Aratana Therapeutics (NASDAQ:PETX) last released its earnings data on Monday, August 12th. The company reported ($4.62) earnings per share for the quarter, beating the analysts’ consensus estimate of ($10.21) by $5.59. On average, analysts predict that Aratana Therapeutics will post $-2.80 earnings per share for the current fiscal year.
Aratana Therapeutics, Inc is a development-stage biopharmaceutical company. As of March 20, 2013, the Company has three licensed compounds in development for six product approvals in cats and dogs in each of the United States and Europe.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.